Abstract：【Objective】To explore the value of serum pepsinogen ratio (PGR) combined with glycoprotein antigen 19-9 (CA19-9) and glycoprotein antigen 72-4 (CA72-4) in the differential diagnosis of benign gastric diseases and gastric cancer.【Methods】The data of 128 patients with suspected gastric cancer were collected and sorted.The levels of PGR and tumor markers (CA19-9 and CA72-4) were analyzed by Logistic regression to explore the related factors affecting gastric cancer. A receiver operating characteristic curve (ROC) was drawn, and the area under the curve (AUC) was used to evaluate the diagnostic value of serum PGR, CA19-9 and CA72-4 levels for gastric cancer. 【Results】Among 128 patients with suspected gastric cancer, 80(62.50%)were diagnosed as the gastric cancer group, and the remaining 48 (37.50%) were the non-gastric cancer group.The gastric cancer group had a lower proportion of previous gastric diseases than the non-gastric cancer group, and the PGR level was lower than that of the non-gastric cancer group, while the levels of CA19-9 and CA72-4 were higher than those in the non-gastric cancer group.The differences were statistically significant (P<0.05). The results of multivariate analysis showed that the existence of past history of gastric disease, high expression levels of CA19-9 and CA72-4, and low expression levels of PGR were all related factors for gastric cancer (P<0.05). ROC analysis showed that the sensitivity of serum PGR, CA19-9, CA72-4 and the combined diagnosis of gastric cancer was 61.25%, 58.75%, 63.75%, and 73.75%, respectively, the specificity was 58.33%, 56.52%, 60.42%, and 75.00%,respectively.The area under curve (AUC) was 0.824, 0.815, 0.894, and 0.916,respectively, and the single diagnostic efficacy of serum PGR, CA19 -9 or CA72-4 was lower than the combined diagnostic efficacy of the three (P<0.05). 【Conclusion】Patients with a history of gastric disease have a higher incidence of gastric cancer.The expression level of PGR in patients with gastric cancer is low, and the expression levels of CA19-9 and CA72-4 are high.Serum PGR, CA19-9 and CA72-4 have clinical diagnostic value for gastric cancer diagnosis, and the combined diagnosis efficiency of the three parameters is even higher.
田晓花, 贾海娟. PGR联合血清肿瘤标志物检测在胃良性疾病与胃癌中的鉴别诊断价值[J]. 医学临床研究, 2022, 39(4): 579-581.
TIAN Xiao-hua, JIA Hai-juan. Value of PGR Combined with Serum Tumor Markers in the Differential Diagnosis of Gastric Benign Diseases and Gastric Cancer. JOURNAL OF CLINICAL RESEARCH, 2022, 39(4): 579-581.
[1] 马颖才,王亚平,刘芝兰,等. 血清学检测联合胃镜检查在青海胃癌高发地区早期胃癌筛查中的价值研究[J].中华消化内镜杂志,2020,37(2):88-93.
[2] ACHARYA A,MARKAR S R,MATAR M,et al. Use of tumor markers in gastrointestinal cancers:surgeon perceptions and cost-benefit trade-off analysis[J].Ann Surg Oncol,2017,24(5):1165-1173.
[3] KIM T S,DA S E,COIT D G,et al. Intratumoral immune response to gastric cancer varies by molecular and histologic subtype[J].Am J Surg Pathol,2019,43(6):851-860.
[4] CHENG H L,LEE Y H,YUAN T M,et al. Update on a tumor-associated NADH oxidase in gastric cancer cell growth[J].World J Gastroenterol,2016,22(10):2900-2905.
[5] 陈小华,薛鸣,王桂臣. 原发性胃癌患者血清中胃蛋白酶原、胃泌素-17水平及其与肿瘤恶性程度的相关性[J].中国医师杂志,2020,22(11):1615-1618.
[6] LIU X,CHOI M G,KIM K,et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features[J].Pathol Res Pract,2020,216(4):152-154.
[7] 张力,汤玮,岳芙蓉,等. 血清PG、G-17、CDH-17在胃癌中的表达及其诊断意义[J].实用癌症杂志,2020,35(8):1258-1261.
[8] SHEN M,WANG H,WEI K,et al. Five common tumor biomarkers and CEA for diagnosing early gastric cancer:A protocol for a network meta-analysis of diagnostic test accuracy[J].Medicine (Baltimore),2018,97(19):e577.
[9] 路静. CA724、CEA、CA242、CA199肿瘤标志物联合检测在胃癌诊断中的应用[J].包头医学院学报,2018,34(6):48-49.
[10] 李永元,刘洪杰. 血清TK1、PG以及CA72-4检测在胃癌筛查以及诊断中的应用价值[J].中国实验诊断学,2017,21(10):1682-1684.
[11] 王书海,吴丽颖,贾国法,等. 淮北地区基于高危因素及不同血清学危险分层方法比较的早期胃癌筛查研究[J].中华消化内镜杂志,2020,37(12):903-909.
[12] 韩梅,连俊,马明杰,等. 血清胃蛋白酶原与肿瘤标志物CEA、CA199、CA242、CA724联合检测对胃癌诊断的价值分析[J].河北医药,2019,41(23):3574-3577.
2022, Vol. 39 
